Veryan has developed a three-dimensional stent technology, BioMimics 3D™, which improves upon the biomechanical and flow characteristics of straight tubular stents, particularly those used in arteries of the leg. Veryan’s stents have a helical shape that mimics the natural geometry of the human vascular system and provoke a swirling blood flow within the stented artery. They also reduce the incidence of kinking or fracture (a common problem in longer stents in limbs) as bending strains are distributed across the entire 3D stent geometry.
Veryan’s stents address unmet clinical need in restenosis, biomechanics and stent fracture in the treatment of peripheral arterial disease (PAD). A recent study showed over 200 million people worldwide live with PAD. Market for treatments is expected to reach $3.3 billion by 2017.
Veryan has already gained a CE Mark enabling sales of its BioMimics 3D™ stent within EEA. In July 2015 the company started a new study in the USA with the aim of securing FDA approval.
20+ years experience in medical devices. Founder of Mednova (sold to Abbott Laboratories). Former senior management roles at CR Bard
Veryan Enters Into Distribution Agreement with Biosensors International for BioMimics 3D StentRead more
Innovations leads £18m series B funding round in VeryanRead more
Two-year follow-up data shows that Veryan's helical geometry BioMimics 3D stent provides improvement in long-term patency when compared to straight nitinol stentRead more
Veryan receives CE Mark for its BioMimics 3D stentRead more
Completed enrolment of patients for its BioMimics 3D trial
Announced the appointment of medical device industry veterans Todd M. Pope and Jeffrey B. Jump as Non-executive directors
Appointment of Nick Yeo, formerly of Light Sciences, Inc., as Chief Operating Officer.
Raised £5m in a round co-led by Innovations and Seroba Kernel Life Sciences.